Shifting Focus in the Therapeutics of Immunobullous Disease

Therapeutics of autoimmune bullous disease has seen a major shift of focus from more global immunosuppression to targeted immunotherapy. Anti CD 20 monoclonal antibody Rituximab revolutionized the therapeutics of autoimmune bullous disease particularly pemphigus. Though it is still being practiced o...

Descripción completa

Detalles Bibliográficos
Autores principales: De, Abhishek, Ansari, Asad, Sharma, Nidhi, Sarda, Aarti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
IJD Symposium
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448263/
https://www.ncbi.nlm.nih.gov/pubmed/28584371
http://dx.doi.org/10.4103/ijd.IJD_199_17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448263/
https://www.ncbi.nlm.nih.gov/pubmed/28584371
http://dx.doi.org/10.4103/ijd.IJD_199_17

Ejemplares similares